echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Stroke: The combination of ticagrelor and aspirin in the treatment of stroke has more advantages than disadvantages

    Stroke: The combination of ticagrelor and aspirin in the treatment of stroke has more advantages than disadvantages

    • Last Update: 2021-09-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Antiplatelet drugs and anticoagulants have been shown to reduce ischemic events in various clinical settings, including specific populations of patients with ischemic stroke or transient ischemic attack (TIA)


    Primary efficacy outcomes (Primary efficacy outcomes) include safety factors, such as bleeding events.


    Primary efficacy outcomes (Primary efficacy outcomes) include safety factors, such as bleeding events.


    With ticagrelor and aspirin prevention of stroke and death in acute stroke or transient ischemic attack trial (Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and Aspirin for Prevention of Stroke and Death; THALES) indicates that this question


    prevention

    Its main efficacy outcome, namely stroke or death, including bleeding events, is also included in the main safety outcome


    In addition, the first published results of THALES focused on relative risk, while absolute risk provided a more useful comparison of risks and benefits


    In THALES, patients were randomly assigned to a 30-day ticagrelor plus aspirin regimen or a matching placebo plus aspirin regimen within 24 hours of the onset of symptoms


    Stroke

    Major ischemic events occurred in 11016 patients (5523 ticagrelor-aspirin and 5493 aspirin), 294 patients (5.


    Major bleeding occurred in 22 patients (0.


    The net clinical impact is in favor of ticagrelor-aspirin (absolute risk reduction 0.


    The significance of this study lies in the discovery: in patients with mild to moderate ischemic stroke or high-risk TIA, the ischemic benefit of 30-day treatment with ticagrelor-aspirin outweighs the risk of bleeding


    Original source:





    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.